journal article·2026-07-10

Construction of Host–Guest Interaction-Based Supramolecular Self-Assemblies for SO 2 -Augmented Chemodynamic Therapy

Xihang Wang, Puwen Song, Mingying Liu, Xihua Li, Yani Suo, Xiao Duan, Yang Bai

ACS Applied Polymer Materials· Volume 8· Issue 13
Publisher page

Abstract

Due to the insufficient H 2 O 2 level and the overexpression of glutathione (GSH) in the tumor microenvironment, the in situ Fenton reaction is markedly suppressed, thereby limiting the efficacy of chemodynamic therapy (CDT). To address this challenge, we herein propose an interesting strategy to enhance CDT efficacy by amplifying intracellular oxidative pressure through in situ SO 2 generation. Accordingly, functional supramolecular polymer self-assemblies (SPSAs@PA) were rationally engineered, enabling GSH-responsive SO 2 release accompanied by effective GSH consumption. The released SO 2 disrupts intracellular redox homeostasis and significantly enhances reactive oxygen species (ROS) accumulation, thereby intensifying oxidative stress for SO 2 -augmented CDT. The detailed mechanism involves: (1) upon GSH stimulation, SPSAs@PA rapidly generate SO 2 in situ, leading to pronounced depletion of intracellular GSH; (2) l -ascorbyl palmitate (PA) participates in redox-related reactions with endogenous proteins, promoting the production of additional H 2 O 2 as substrates for the Fenton reaction, thus generating more ·OH; and (3) the elevated oxidative pressure and ROS levels synergistically amplify CDT-induced oxidative damage. Based on this mechanism, SO 2 -augmented CDT can be effectively achieved through in situ SO 2 generation, GSH depletion, and ROS enhancement. Notably, SPSAs@PA exhibited remarkable anticancer efficacy, with cell lethality reaching up to 96% at a concentration of 7 μg/mL of 2,4-dinitrobenzenesulfonyl chloride-modified ferrocene (Fc-DNBS), demonstrating that this strategy of in situ SO 2 -induced oxidative pressure amplification is highly effective for enhancing CDT efficacy in tumor therapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Supramolecular Chemistry and Complexes · Supramolecular Self-Assembly in Materials

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Shaanxi Key Laboratory of Chemical Additives for Industry, College of Chemistry and Chemical Engineering

Shaanxi University of Science and Technology

College of Chemistry and Chemical Engineering

Northwestern Polytechnical University

Changzhi Key Laboratory of Drug Molecular Design and Innovative Pharmaceutics, Shanxi Provincial Department-Municipal Key Laboratory Cultivation Base for Quality Enhancement and Utilization of Shangdang Chinese Medicinal Materials, School of Pharmacy

Changzhi Medical College

Funding

Shanxi Scholarship Council of China · Natural Science Foundation of Shaanxi Province · Top Young Talented Scientist in Shanxi Province · National Natural Science Foundation of China (NSFC)

References (42)

Show source-provided references
1. 10.1021/acsnano.9b0495410.1021/acsnano.9b04954 ↗
2. 10.1016/j.cej.2025.16254410.1016/j.cej.2025.162544 ↗
3. 10.1002/smtd.20230134910.1002/smtd.202301349 ↗
4. 10.1016/j.ccr.2025.21674610.1016/j.ccr.2025.216746 ↗
5. 10.1016/j.cej.2023.14531610.1016/j.cej.2023.145316 ↗
6. 10.1002/smll.20250272710.1002/smll.202502727 ↗
7. 10.3389/fphar.2023.130346510.3389/fphar.2023.1303465 ↗
8. 10.1021/acsami.4c1347810.1021/acsami.4c13478 ↗
9. 10.1016/j.jhazmat.2024.13629110.1016/j.jhazmat.2024.136291 ↗
10. 10.1021/acsapm.4c0124910.1021/acsapm.4c01249 ↗
11. 10.1002/smll.20220255810.1002/smll.202202558 ↗
12. 10.1021/acsami.5c0131010.1021/acsami.5c01310 ↗
13. 10.1021/acsnano.8b0870010.1021/acsnano.8b08700 ↗
14. 10.1002/anie.20242236210.1002/anie.202422362 ↗
15. 10.1002/advs.20240557510.1002/advs.202405575 ↗
16. 10.1016/j.biomaterials.2018.02.01110.1016/j.biomaterials.2018.02.011 ↗
17. 10.1039/D4TB01468E10.1039/D4TB01468E ↗
18. 10.1039/D4TB02848A10.1039/D4TB02848A ↗
19. 10.1002/adfm.20240269210.1002/adfm.202402692 ↗
20. 10.1021/acsami.4c1346510.1021/acsami.4c13465 ↗
21. 10.1002/smll.20240545710.1002/smll.202405457 ↗
22. 10.1016/j.jcis.2025.01.14910.1016/j.jcis.2025.01.149 ↗
23. 10.1002/smll.20250172110.1002/smll.202501721 ↗
24. 10.1002/adfm.20240746810.1002/adfm.202407468 ↗
25. 10.1002/smll.20230908610.1002/smll.202309086 ↗
26. 10.1002/advs.20241383310.1002/advs.202413833 ↗
27. 10.1016/j.bioactmat.2025.04.02710.1016/j.bioactmat.2025.04.027 ↗
28. 10.1039/D5NR00808E10.1039/D5NR00808E ↗
29. 10.1016/j.mtnano.2023.10042210.1016/j.mtnano.2023.100422 ↗
30. 10.1016/j.jconrel.2009.09.01010.1016/j.jconrel.2009.09.010 ↗
31. 10.1016/j.nantod.2023.10189910.1016/j.nantod.2023.101899 ↗
32. 10.1016/j.matdes.2023.11262210.1016/j.matdes.2023.112622 ↗
33. 10.1016/j.ijpharm.2023.12282210.1016/j.ijpharm.2023.122822 ↗
34. 10.1021/acsami.4c1363010.1021/acsami.4c13630 ↗
35. 10.1021/acsnano.5c0189410.1021/acsnano.5c01894 ↗
36. 10.1021/acsmacrolett.4c0068710.1021/acsmacrolett.4c00687 ↗
37. 10.1002/advs.20240944210.1002/advs.202409442 ↗
38. 10.1016/j.matdes.2023.11241410.1016/j.matdes.2023.112414 ↗
39. 10.1002/smll.20230984210.1002/smll.202309842 ↗
40. 10.1021/acsami.2c0991210.1021/acsami.2c09912 ↗
41. 10.1016/j.cclet.2022.05.06610.1016/j.cclet.2022.05.066 ↗
42. 10.1007/s12274-023-5858-910.1007/s12274-023-5858-9 ↗